The Life Sciences team advised Monte Rosa Therapeutics on its $95 million Series C financing.
Monte Rosa Therapeutics is a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins.
The proceeds of the financing will be used to advance the company’s lead development candidate into the clinic, accelerate pipeline growth, and bolster its platform capabilities to rationally design and develop small molecule degraders (also known as molecular glues) that hijack the body’s innate ability to degrade proteins. Through this approach, Monte Rosa aims to eradicate undruggable proteins that cause or drive the progression of genomically-defined diseases intractable to standard care, including cancer.
The Goodwin team was led by Rob Puopolo, Mulon Luo, Dan Hughes and included Richard Matheny.
For more details, read the press release and articles in Endpoints, Fierce Biotech, and Venture Capital Journal.